Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

Fewer patients experienced a first hospital admission for any indication and for serious adverse events while on semaglutide.

Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of ...

Trying to lose weight quickly can feel like an uphill battle, but weight loss medications like Ozempic or Wegovy can speed up ...

In a groundbreaking new study, the active ingredient in Ozempic was found to be so effective at treating arthritis that ...

SAN ANTONIO — Treatment with once-weekly semaglutide 2.4 mg (Wegovy) significantly reduced hospital admissions for all causes — not just cardiac — and overall hospitalization time in people with ...

Researchers found a significant reduction in the risk for a first-time AD diagnosis in association with semaglutide.

Semaglutide met both primary endpoints in part 1 of ESSENCE. Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.